5 percent of patients with metastatic breast cancer responded to treatment with TLC
D-99 (liposomal doxorubicin) in combination with two other commonly used anti-cancer drugs.
While the company had yet to report 1992 sales at press time, TLC
Beatrice expected a modest decrease from its $1.
Beatrice International is a multinational food company with operations principally in western Europe.
Moreover, the fact that TLC
D-99's favorable toxicity profile was reconfirmed also is good news.
Kashi is taking the new TLC
granola bar line on the road as part of its Day of Change(TM) tour, a seven month, cross-country campaign designed to help inspire people to make healthy changes in their lives.
PowerShot Pool(TM) is appealing to everyone; professional pool players, amateur players, mature players with physical limitations and young kids who want to learn but can't reach a table," said Bob Goodman, Director of Sales at TLC
Investigators from the Webb-Waring Institute of the University of Colorado, one of the country's leading ARDS research and teaching centers, presented findings from their ARDS experiments with TLC
C-53, and researchers from the University of Texas Medical School, a prestigious heart research center, reported results from experiments with the drug in models of heart attacks.
HIGH RESPONSE RATE REPORTED IN BREAST CANCER STUDY WITH TLC
BOSTON -- A new partnership between learning solutions provider Total Learning Concepts (TLC
), a Publicis Healthcare Communications Group (PHCG) company, and online employee assessment company Censeo Corporation will offer TLC
clients access to powerful assessment delivery and reporting capabilities designed to increase the effectiveness of learning.
Proceeds from the offering are expected to be used for the development and clinical testing of the company's self-funded products, including TLC
G-65 and TLC
LOUIS -- TLC
Vision Corporation (NASDAQ: TLCV) (TSX: TLC), North America's premiere eye care services company, announced today the acquisition of a leading refractive center in Greensboro, North Carolina and a mobile cataract company in Louisville, Kentucky.
G-65 demonstrated that the drug was active and well tolerated.
The company has commitments from Owner Operators that will allow TLC
to have 14 leased-on trucks on the road by April 28th.
Ostro introduced TLC
C-53, the company's new cell adhesion antagonist being developed for the treatment of a variety of acute inflammatory and vaso-occlusive conditions, while Baker focused primarily on the progress made in Phase II clinical trials of the company's three lead products.
In doing so, TLC
has successfully secured the necessary DOT permits, attained Tennessee registration and acquired an ultra-low fleet insurance program.